ID   UBR5_HUMAN              Reviewed;        2799 AA.
AC   O95071; B2RP24; J3KMW7; O94970; Q9NPL3;
DT   05-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2001, sequence version 2.
DT   10-MAY-2017, entry version 182.
DE   RecName: Full=E3 ubiquitin-protein ligase UBR5;
DE            EC=2.3.2.26;
DE   AltName: Full=E3 ubiquitin-protein ligase, HECT domain-containing 1;
DE   AltName: Full=HECT-type E3 ubiquitin transferase UBR5;
DE   AltName: Full=Hyperplastic discs protein homolog;
DE            Short=hHYD;
DE   AltName: Full=Progestin-induced protein;
GN   Name=UBR5; Synonyms=EDD, EDD1, HYD, KIAA0896;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Heart, and Placenta;
RX   PubMed=10030672; DOI=10.1038/sj.onc.1202249;
RA   Callaghan M.J., Russell A.J., Woollatt E., Sutherland G.R.,
RA   Sutherland R.L., Watts C.K.W.;
RT   "Identification of a human HECT family protein with homology to the
RT   Drosophila tumor suppressor gene hyperplastic discs.";
RL   Oncogene 17:3479-3491(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH TOPBP1.
RC   TISSUE=Fetal brain;
RX   PubMed=11714696; DOI=10.1074/jbc.M104347200;
RA   Honda Y., Tojo M., Matsuzaki K., Anan T., Matsumoto M., Ando M.,
RA   Saya H., Nakao M.;
RT   "Cooperation of HECT-domain ubiquitin ligase hHYD and DNA
RT   topoisomerase II-binding protein for DNA damage response.";
RL   J. Biol. Chem. 277:3599-3605(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=10048485; DOI=10.1093/dnares/5.6.355;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M.,
RA   Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 5:355-364(1998).
RN   [4]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [5]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R., Ishikawa K., Suyama M.;
RL   Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1746, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1969, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1308; SER-1549; THR-1969
RP   AND SER-2486, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT THR-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   INTERACTION WITH EDVP COMPLEX.
RX   PubMed=19287380; DOI=10.1038/ncb1848;
RA   Maddika S., Chen J.;
RT   "Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3
RT   ligase.";
RL   Nat. Cell Biol. 11:409-419(2009).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2486, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1549 AND THR-1969, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   FUNCTION AS CDK9 UBIQUITIN LIGASE, AND INTERACTION WITH CDK9 AND
RP   TFIIS/TCEA1.
RX   PubMed=21127351; DOI=10.1074/jbc.M110.176628;
RA   Cojocaru M., Bouchard A., Cloutier P., Cooper J.J., Varzavand K.,
RA   Price D.H., Coulombe B.;
RT   "Transcription factor IIS cooperates with the E3 ligase UBR5 to
RT   ubiquitinate the CDK9 subunit of the positive transcription elongation
RT   factor B.";
RL   J. Biol. Chem. 286:5012-5022(2011).
RN   [19]
RP   PHOSPHORYLATION AT SER-110; SER-327; SER-352; SER-578; SER-612;
RP   THR-637; SER-808; SER-928; SER-1018; THR-1115; THR-1135; SER-1227;
RP   SER-1308; SER-1355; SER-1375; SER-1481; THR-1736; SER-1741; SER-1780;
RP   THR-1969; SER-2026; SER-2028; THR-2030; SER-2076; THR-2213; SER-2289
RP   AND SER-2484.
RX   PubMed=21924388; DOI=10.1016/j.jprot.2011.08.023;
RA   Bethard J.R., Zheng H., Roberts L., Eblen S.T.;
RT   "Identification of phosphorylation sites on the E3 ubiquitin ligase
RT   UBR5/EDD.";
RL   J. Proteomics 75:603-609(2011).
RN   [20]
RP   FUNCTION IN UBIQUITINATION OF PCK1.
RX   PubMed=21726808; DOI=10.1016/j.molcel.2011.04.028;
RA   Jiang W., Wang S., Xiao M., Lin Y., Zhou L., Lei Q., Xiong Y.,
RA   Guan K.L., Zhao S.;
RT   "Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation
RT   via recruiting the UBR5 ubiquitin ligase.";
RL   Mol. Cell 43:33-44(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-327; SER-1549 AND
RP   SER-2486, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   FUNCTION.
RX   PubMed=22884692; DOI=10.1016/j.cell.2012.06.039;
RA   Gudjonsson T., Altmeyer M., Savic V., Toledo L., Dinant C., Grofte M.,
RA   Bartkova J., Poulsen M., Oka Y., Bekker-Jensen S., Mailand N.,
RA   Neumann B., Heriche J.K., Shearer R., Saunders D., Bartek J.,
RA   Lukas J., Lukas C.;
RT   "TRIP12 and UBR5 Suppress Spreading of Chromatin Ubiquitylation at
RT   Damaged Chromosomes.";
RL   Cell 150:697-709(2012).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-110; SER-327; SER-578;
RP   SER-612; SER-808; SER-1308; SER-1549; THR-1969; SER-2241; SER-2469 AND
RP   SER-2486, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   INTERACTION WITH PIH1D1.
RX   PubMed=24656813; DOI=10.1016/j.celrep.2014.03.013;
RA   Horejsi Z., Stach L., Flower T.G., Joshi D., Flynn H., Skehel J.M.,
RA   O'Reilly N.J., Ogrodowicz R.W., Smerdon S.J., Boulton S.J.;
RT   "Phosphorylation-dependent PIH1D1 interactions define substrate
RT   specificity of the R2TP cochaperone complex.";
RL   Cell Rep. 7:19-26(2014).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1549 AND SER-1990, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.04 ANGSTROMS) OF 2391-2455, AND MUTAGENESIS
RP   OF CYS-2768.
RX   PubMed=11287654; DOI=10.1073/pnas.071552198;
RA   Deo R.C., Sonenberg N., Burley S.K.;
RT   "X-ray structure of the human hyperplastic discs protein: an ortholog
RT   of the C-terminal domain of poly(A)-binding protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:4414-4419(2001).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which is a component of the
CC       N-end rule pathway. Recognizes and binds to proteins bearing
CC       specific N-terminal residues that are destabilizing according to
CC       the N-end rule, leading to their ubiquitination and subsequent
CC       degradation (By similarity). Involved in maturation and/or
CC       transcriptional regulation of mRNA by activating CDK9 by
CC       polyubiquitination. May play a role in control of cell cycle
CC       progression. May have tumor suppressor function. Regulates DNA
CC       topoisomerase II binding protein (TopBP1) in the DNA damage
CC       response. Plays an essential role in extraembryonic development.
CC       Ubiquitinates acetylated PCK1. Also acts as a regulator of DNA
CC       damage response by acting as a suppressor of RNF168, an E3
CC       ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-
CC       linked histone H2A and H2AX at DNA damage sites, thereby acting as
CC       a guard against excessive spreading of ubiquitinated chromatin at
CC       damaged chromosomes. {ECO:0000250, ECO:0000269|PubMed:21127351,
CC       ECO:0000269|PubMed:21726808, ECO:0000269|PubMed:22884692}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Binds TOPBP1. Associates with CDK9 and TFIIS/TCEA1 and
CC       forms a transcription regulatory complex made of CDK9, RNAP II,
CC       UBR5 and TFIIS/TCEA1 that can stimulate target gene transcription
CC       (e.g. gamma fibrinogen/FGG) by recruiting their promoters.
CC       Associates with the E3 ligase complex containing DYRK2, EDD/UBR5,
CC       DDB1 and DCAF1 proteins (EDVP complex). Interacts directly with
CC       DYRK2. Interacts with PIH1D1 (PubMed:24656813).
CC       {ECO:0000269|PubMed:11714696, ECO:0000269|PubMed:19287380,
CC       ECO:0000269|PubMed:21127351, ECO:0000269|PubMed:24656813}.
CC   -!- INTERACTION:
CC       P35222:CTNNB1; NbExp=6; IntAct=EBI-358329, EBI-491549;
CC       P49841:GSK3B; NbExp=8; IntAct=EBI-358329, EBI-373586;
CC       Q9BPZ3:PAIP2; NbExp=5; IntAct=EBI-358329, EBI-2957445;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O95071-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O95071-2; Sequence=VSP_054399;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Most abundant in testis and
CC       expressed at high levels in brain, pituitary and kidney.
CC   -!- MISCELLANEOUS: A cysteine residue is required for ubiquitin-
CC       thioester formation.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA74919.3; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF006010; AAD01259.2; -; mRNA.
DR   EMBL; U95000; AAF88143.1; -; mRNA.
DR   EMBL; AB020703; BAA74919.3; ALT_INIT; mRNA.
DR   EMBL; AP002907; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP002981; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC137234; AAI37235.1; -; mRNA.
DR   CCDS; CCDS34933.1; -. [O95071-1]
DR   CCDS; CCDS64946.1; -. [O95071-2]
DR   RefSeq; NP_001269802.1; NM_001282873.1. [O95071-2]
DR   RefSeq; NP_056986.2; NM_015902.5. [O95071-1]
DR   UniGene; Hs.492445; -.
DR   PDB; 1I2T; X-ray; 1.04 A; A=2393-2453.
DR   PDB; 2QHO; X-ray; 1.85 A; B/D/F/H=180-230.
DR   PDB; 3PT3; X-ray; 1.97 A; A/B=2687-2799.
DR   PDBsum; 1I2T; -.
DR   PDBsum; 2QHO; -.
DR   PDBsum; 3PT3; -.
DR   ProteinModelPortal; O95071; -.
DR   SMR; O95071; -.
DR   BioGrid; 119501; 137.
DR   DIP; DIP-32930N; -.
DR   IntAct; O95071; 68.
DR   MINT; MINT-196086; -.
DR   STRING; 9606.ENSP00000429084; -.
DR   iPTMnet; O95071; -.
DR   PhosphoSitePlus; O95071; -.
DR   BioMuta; UBR5; -.
DR   EPD; O95071; -.
DR   MaxQB; O95071; -.
DR   PaxDb; O95071; -.
DR   PeptideAtlas; O95071; -.
DR   PRIDE; O95071; -.
DR   Ensembl; ENST00000220959; ENSP00000220959; ENSG00000104517. [O95071-2]
DR   Ensembl; ENST00000520539; ENSP00000429084; ENSG00000104517. [O95071-1]
DR   GeneID; 51366; -.
DR   KEGG; hsa:51366; -.
DR   UCSC; uc003ykr.3; human. [O95071-1]
DR   CTD; 51366; -.
DR   DisGeNET; 51366; -.
DR   GeneCards; UBR5; -.
DR   H-InvDB; HIX0025542; -.
DR   HGNC; HGNC:16806; UBR5.
DR   HPA; HPA053688; -.
DR   MIM; 608413; gene.
DR   neXtProt; NX_O95071; -.
DR   OpenTargets; ENSG00000104517; -.
DR   PharmGKB; PA162408175; -.
DR   eggNOG; KOG0943; Eukaryota.
DR   eggNOG; COG5021; LUCA.
DR   GeneTree; ENSGT00850000132302; -.
DR   HOGENOM; HOG000046848; -.
DR   HOVERGEN; HBG096012; -.
DR   InParanoid; O95071; -.
DR   KO; K10593; -.
DR   OMA; ENSLYWW; -.
DR   OrthoDB; EOG091G005O; -.
DR   PhylomeDB; O95071; -.
DR   TreeFam; TF314406; -.
DR   BRENDA; 6.3.2.19; 2681.
DR   SignaLink; O95071; -.
DR   SIGNOR; O95071; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; UBR5; human.
DR   EvolutionaryTrace; O95071; -.
DR   GeneWiki; UBR5; -.
DR   GenomeRNAi; 51366; -.
DR   PRO; PR:O95071; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000104517; -.
DR   CleanEx; HS_UBR5; -.
DR   ExpressionAtlas; O95071; baseline and differential.
DR   Genevisible; O95071; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HGNC.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:MGI.
DR   GO; GO:0043234; C:protein complex; IDA:MGI.
DR   GO; GO:0003723; F:RNA binding; IEA:InterPro.
DR   GO; GO:0043130; F:ubiquitin binding; IEA:InterPro.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; TAS:ProtInc.
DR   GO; GO:0034450; F:ubiquitin-ubiquitin ligase activity; IDA:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0008283; P:cell proliferation; TAS:ProtInc.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:HGNC.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:2000780; P:negative regulation of double-strand break repair; IMP:UniProtKB.
DR   GO; GO:1901315; P:negative regulation of histone H2A K63-linked ubiquitination; IMP:UniProtKB.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0035413; P:positive regulation of catenin import into nucleus; IMP:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:MGI.
DR   GO; GO:0033160; P:positive regulation of protein import into nucleus, translocation; IMP:BHF-UCL.
DR   GO; GO:0050847; P:progesterone receptor signaling pathway; IDA:HGNC.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:BHF-UCL.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; TAS:ProtInc.
DR   CDD; cd14423; CUE_UBR5; 1.
DR   InterPro; IPR024725; E3_UbLigase_EDD_UBA.
DR   InterPro; IPR000569; HECT_dom.
DR   InterPro; IPR002004; PABP_HYD.
DR   InterPro; IPR009091; RCC1/BLIP-II.
DR   InterPro; IPR003126; Znf_UBR.
DR   Pfam; PF11547; E3_UbLigase_EDD; 1.
DR   Pfam; PF00632; HECT; 1.
DR   Pfam; PF00658; PABP; 1.
DR   SMART; SM00119; HECTc; 1.
DR   SMART; SM00517; PolyA; 1.
DR   SMART; SM00396; ZnF_UBR1; 1.
DR   SUPFAM; SSF50985; SSF50985; 1.
DR   SUPFAM; SSF56204; SSF56204; 2.
DR   SUPFAM; SSF63570; SSF63570; 1.
DR   PROSITE; PS50237; HECT; 1.
DR   PROSITE; PS51309; PABC; 1.
DR   PROSITE; PS51157; ZF_UBR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   DNA damage; DNA repair; Metal-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transferase;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2   2799       E3 ubiquitin-protein ligase UBR5.
FT                                /FTId=PRO_0000086931.
FT   DOMAIN     2377   2454       PABC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00641}.
FT   DOMAIN     2462   2799       HECT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00104}.
FT   ZN_FING    1177   1245       UBR-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00508}.
FT   COMPBIAS    940    945       Poly-Glu.
FT   COMPBIAS    980    985       Poly-Ser.
FT   COMPBIAS   1528   1537       Poly-Ser.
FT   COMPBIAS   1671   1681       Poly-Ser.
FT   COMPBIAS   1762   1768       Poly-Ala.
FT   COMPBIAS   1986   1997       Asp/Glu-rich (acidic).
FT   COMPBIAS   2036   2059       Pro-rich.
FT   COMPBIAS   2329   2348       Arg/Glu-rich (mixed charge).
FT   COMPBIAS   2357   2366       Arg/Asp-rich (mixed charge).
FT   COMPBIAS   2489   2500       Asp/Glu-rich (acidic).
FT   COMPBIAS   2737   2757       Pro-rich.
FT   ACT_SITE   2768   2768       Glycyl thioester intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00104}.
FT   MOD_RES       2      2       N-acetylthreonine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES     110    110       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:21924388}.
FT   MOD_RES     327    327       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:21924388}.
FT   MOD_RES     352    352       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES     578    578       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:21924388}.
FT   MOD_RES     612    612       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:21924388}.
FT   MOD_RES     637    637       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES     808    808       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:21924388}.
FT   MOD_RES     928    928       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1018   1018       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1115   1115       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1135   1135       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1227   1227       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1308   1308       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1355   1355       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1375   1375       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1481   1481       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1549   1549       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1736   1736       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1741   1741       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1746   1746       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:15592455}.
FT   MOD_RES    1780   1780       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1969   1969       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:21924388}.
FT   MOD_RES    1990   1990       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2026   2026       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    2028   2028       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    2030   2030       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    2076   2076       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    2213   2213       Phosphothreonine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    2241   2241       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2289   2289       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    2469   2469       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2484   2484       Phosphoserine.
FT                                {ECO:0000269|PubMed:21924388}.
FT   MOD_RES    2486   2486       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ    2474   2474       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10048485}.
FT                                /FTId=VSP_054399.
FT   VARIANT    2150   2150       S -> R (in dbSNP:rs1062822).
FT                                /FTId=VAR_051466.
FT   MUTAGEN    2768   2768       C->A: Loss of ubiquitin binding.
FT                                {ECO:0000269|PubMed:11287654}.
FT   CONFLICT    134    134       S -> P (in Ref. 2; AAF88143).
FT                                {ECO:0000305}.
FT   CONFLICT    229    229       E -> K (in Ref. 2; AAF88143).
FT                                {ECO:0000305}.
FT   CONFLICT    258    258       S -> Y (in Ref. 2; AAF88143).
FT                                {ECO:0000305}.
FT   CONFLICT    374    375       IG -> M (in Ref. 2; AAF88143).
FT                                {ECO:0000305}.
FT   CONFLICT    772    772       D -> H (in Ref. 2; AAF88143).
FT                                {ECO:0000305}.
FT   CONFLICT    780    780       Q -> R (in Ref. 2; AAF88143).
FT                                {ECO:0000305}.
FT   CONFLICT    884    884       D -> G (in Ref. 2; AAF88143).
FT                                {ECO:0000305}.
FT   CONFLICT   1811   1811       S -> P (in Ref. 2; AAF88143).
FT                                {ECO:0000305}.
FT   CONFLICT   2144   2144       L -> H (in Ref. 2; AAF88143).
FT                                {ECO:0000305}.
FT   CONFLICT   2282   2282       K -> R (in Ref. 2; AAF88143).
FT                                {ECO:0000305}.
FT   CONFLICT   2489   2489       D -> N (in Ref. 2; AAF88143).
FT                                {ECO:0000305}.
FT   HELIX       182    184       {ECO:0000244|PDB:2QHO}.
FT   HELIX       187    196       {ECO:0000244|PDB:2QHO}.
FT   HELIX       202    211       {ECO:0000244|PDB:2QHO}.
FT   TURN        212    214       {ECO:0000244|PDB:2QHO}.
FT   HELIX       216    224       {ECO:0000244|PDB:2QHO}.
FT   HELIX      2394   2408       {ECO:0000244|PDB:1I2T}.
FT   HELIX      2410   2412       {ECO:0000244|PDB:1I2T}.
FT   HELIX      2413   2420       {ECO:0000244|PDB:1I2T}.
FT   HELIX      2425   2433       {ECO:0000244|PDB:1I2T}.
FT   HELIX      2435   2452       {ECO:0000244|PDB:1I2T}.
FT   HELIX      2687   2692       {ECO:0000244|PDB:3PT3}.
FT   STRAND     2695   2698       {ECO:0000244|PDB:3PT3}.
FT   HELIX      2704   2720       {ECO:0000244|PDB:3PT3}.
FT   HELIX      2723   2734       {ECO:0000244|PDB:3PT3}.
FT   STRAND     2751   2756       {ECO:0000244|PDB:3PT3}.
FT   STRAND     2764   2766       {ECO:0000244|PDB:3PT3}.
FT   TURN       2767   2770       {ECO:0000244|PDB:3PT3}.
FT   STRAND     2771   2775       {ECO:0000244|PDB:3PT3}.
FT   HELIX      2780   2791       {ECO:0000244|PDB:3PT3}.
SQ   SEQUENCE   2799 AA;  309352 MW;  871300DB404FF561 CRC64;
     MTSIHFVVHP LPGTEDQLND RLREVSEKLN KYNLNSHPPL NVLEQATIKQ CVVGPNHAAF
     LLEDGRVCRI GFSVQPDRLE LGKPDNNDGS KLNSNSGAGR TSRPGRTSDS PWFLSGSETL
     GRLAGNTLGS RWSSGVGGSG GGSSGRSSAG ARDSRRQTRV IRTGRDRGSG LLGSQPQPVI
     PASVIPEELI SQAQVVLQGK SRSVIIRELQ RTNLDVNLAV NNLLSRDDED GDDGDDTASE
     SYLPGEDLMS LLDADIHSAH PSVIIDADAM FSEDISYFGY PSFRRSSLSR LGSSRVLLLP
     LERDSELLRE RESVLRLRER RWLDGASFDN ERGSTSKEGE PNLDKKNTPV QSPVSLGEDL
     QWWPDKDGTK FICIGALYSE LLAVSSKGEL YQWKWSESEP YRNAQNPSLH HPRATFLGLT
     NEKIVLLSAN SIRATVATEN NKVATWVDET LSSVASKLEH TAQTYSELQG ERIVSLHCCA
     LYTCAQLENS LYWWGVVPFS QRKKMLEKAR AKNKKPKSSA GISSMPNITV GTQVCLRNNP
     LYHAGAVAFS ISAGIPKVGV LMESVWNMND SCRFQLRSPE SLKNMEKASK TTEAKPESKQ
     EPVKTEMGPP PSPASTCSDA SSIASSASMP YKRRRSTPAP KEEEKVNEEQ WSLREVVFVE
     DVKNVPVGKV LKVDGAYVAV KFPGTSSNTN CQNSSGPDAD PSSLLQDCRL LRIDELQVVK
     TGGTPKVPDC FQRTPKKLCI PEKTEILAVN VDSKGVHAVL KTGNWVRYCI FDLATGKAEQ
     ENNFPTSSIA FLGQNERNVA IFTAGQESPI ILRDGNGTIY PMAKDCMGGI RDPDWLDLPP
     ISSLGMGVHS LINLPANSTI KKKAAVIIMA VEKQTLMQHI LRCDYEACRQ YLMNLEQAVV
     LEQNLQMLQT FISHRCDGNR NILHACVSVC FPTSNKETKE EEEAERSERN TFAERLSAVE
     AIANAISVVS SNGPGNRAGS SSSRSLRLRE MMRRSLRAAG LGRHEAGASS SDHQDPVSPP
     IAPPSWVPDP PAMDPDGDID FILAPAVGSL TTAATGTGQG PSTSTIPGPS TEPSVVESKD
     RKANAHFILK LLCDSVVLQP YLRELLSAKD ARGMTPFMSA VSGRAYPAAI TILETAQKIA
     KAEISSSEKE EDVFMGMVCP SGTNPDDSPL YVLCCNDTCS FTWTGAEHIN QDIFECRTCG
     LLESLCCCTE CARVCHKGHD CKLKRTSPTA YCDCWEKCKC KTLIAGQKSA RLDLLYRLLT
     ATNLVTLPNS RGEHLLLFLV QTVARQTVEH CQYRPPRIRE DRNRKTASPE DSDMPDHDLE
     PPRFAQLALE RVLQDWNALK SMIMFGSQEN KDPLSASSRI GHLLPEEQVY LNQQSGTIRL
     DCFTHCLIVK CTADILLLDT LLGTLVKELQ NKYTPGRREE AIAVTMRFLR SVARVFVILS
     VEMASSKKKN NFIPQPIGKC KRVFQALLPY AVEELCNVAE SLIVPVRMGI ARPTAPFTLA
     STSIDAMQGS EELFSVEPLP PRPSSDQSSS SSQSQSSYII RNPQQRRISQ SQPVRGRDEE
     QDDIVSADVE EVEVVEGVAG EEDHHDEQEE HGEENAEAEG QHDEHDEDGS DMELDLLAAA
     ETESDSESNH SNQDNASGRR SVVTAATAGS EAGASSVPAF FSEDDSQSND SSDSDSSSSQ
     SDDIEQETFM LDEPLERTTN SSHANGAAQA PRSMQWAVRN TQHQRAASTA PSSTSTPAAS
     SAGLIYIDPS NLRRSGTIST SAAAAAAALE ASNASSYLTS ASSLARAYSI VIRQISDLMG
     LIPKYNHLVY SQIPAAVKLT YQDAVNLQNY VEEKLIPTWN WMVSIMDSTE AQLRYGSALA
     SAGDPGHPNH PLHASQNSAR RERMTAREEA SLRTLEGRRR ATLLSARQGM MSARGDFLNY
     ALSLMRSHND EHSDVLPVLD VCSLKHVAYV FQALIYWIKA MNQQTTLDTP QLERKRTREL
     LELGIDNEDS EHENDDDTNQ SATLNDKDDD SLPAETGQNH PFFRRSDSMT FLGCIPPNPF
     EVPLAEAIPL ADQPHLLQPN ARKEDLFGRP SQGLYSSSAS SGKCLMEVTV DRNCLEVLPT
     KMSYAANLKN VMNMQNRQKK EGEEQPVLPE ETESSKPGPS AHDLAAQLKS SLLAEIGLTE
     SEGPPLTSFR PQCSFMGMVI SHDMLLGRWR LSLELFGRVF MEDVGAEPGS ILTELGGFEV
     KESKFRREME KLRNQQSRDL SLEVDRDRDL LIQQTMRQLN NHFGRRCATT PMAVHRVKVT
     FKDEPGEGSG VARSFYTAIA QAFLSNEKLP NLECIQNANK GTHTSLMQRL RNRGERDRER
     EREREMRRSS GLRAGSRRDR DRDFRRQLSI DTRPFRPASE GNPSDDPEPL PAHRQALGER
     LYPRVQAMQP AFASKITGML LELSPAQLLL LLASEDSLRA RVDEAMELII AHGRENGADS
     ILDLGLVDSS EKVQQENRKR HGSSRSVVDM DLDDTDDGDD NAPLFYQPGK RGFYTPRPGK
     NTEARLNCFR NIGRILGLCL LQNELCPITL NRHVIKVLLG RKVNWHDFAF FDPVMYESLR
     QLILASQSSD ADAVFSAMDL AFAIDLCKEE GGGQVELIPN GVNIPVTPQN VYEYVRKYAE
     HRMLVVAEQP LHAMRKGLLD VLPKNSLEDL TAEDFRLLVN GCGEVNVQML ISFTSFNDES
     GENAEKLLQF KRWFWSIVEK MSMTERQDLV YFWTSSPSLP ASEEGFQPMP SITIRPPDDQ
     HLPTANTCIS RLYVPLYSSK QILKQKLLLA IKTKNFGFV
//
